Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 21:4:143.
doi: 10.3389/fphar.2013.00143.

The use of lipid-based nanocarriers for targeted pain therapies

Susan Hua  1 , Sherry Y Wu
Affiliations
Review

The use of lipid-based nanocarriers for targeted pain therapies

Susan Hua et al. Front Pharmacol. .

Abstract

Sustained delivery of analgesic agents at target sites remains a critical issue for effective pain management. The use of nanocarriers has been reported to facilitate effective delivery of these agents to target sites while minimizing systemic toxicity. These include the use of biodegradable liposomal or polymeric carriers. Of these, liposomes present as an attractive delivery system due to their flexible physicochemical properties which allow easy manipulation in order to address different delivery considerations. Their favorable toxicity profiles and ease of large scale production also make their clinical use feasible. In this review, we will discuss the concept of using liposomes as a drug delivery carrier, their in vitro characteristics as well as in vivo behavior. Current advances in the targeted liposomal delivery of analgesic agents and their impacts on the field of pain management will be presented.

Keywords: inflammation; liposomes; nanocarriers; pain; targeted drug delivery.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Use of nanocarriers for pain management.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allen T. M., Cullis P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Del. Rev. 65 36–48 10.1016/j.addr.2012.09.037 - DOI - PubMed
    1. Antohe F., Lin L., Kao G. Y., Poznansky M. J., Allen T. M. (2004). Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine. J. Liposome Res. 14 1–25 10.1081/LPR-120039660 - DOI - PubMed
    1. Avnir Y., Ulmansky R., Wasserman V., Even-Chen S., Broyer M., Barenholz Y., et al. (2008). Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum. 58 119–129 10.1002/art.23230 - DOI - PubMed
    1. Bansal S. S., Joshi A., Bansal A. K. (2007). New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging 24 441–451 10.2165/00002512-200724060-00001 - DOI - PubMed
    1. Bendas G. (2001). Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 15 215–224 10.2165/00063030-200115040-00002 - DOI - PubMed

LinkOut - more resources